The MACS GMP Aspergillus fumigatus Lysate consists of disrupted Aspergillus fumigatus mycel from the ATCC strain 46645. It has been developed for efficient in vitro stimulation and subsequent isolation of A. fumigatus-specific CD4+ and CD8+ T cells.
MACS GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.
A. fumigatus is one of the most ubiquitous of the airborne fungi. Humans and animals constantly inhale numerous spores of this fungus. A. fumigatus has become the most prevalent airborne fungal pathogen, causing severe and usually fatal invasive infections in immunocompromised hosts in developed countries. An increase in invasive aspergillosis (IA) has been observed.1,2
The in vitro stimulation of A. fumigatus-specific CD4+ and CD8+ T cells with MACS GMP Aspergillus fumigatus Lysate leads to the upregulation of activation markers, such as CD137. The presence of CD137 on the cell surface then permits the enrichment of A. fumigatus-specific effector/memory T cells with the use of the CliniMACS CD137 Product Line.
Adoptive transfer of A. fumigatus-specific T cells may be an effective tool for the treatment of post-engraftment invasive aspergillosis (IA) in hematopoietic stem cell transplant (HSCT) recipients.
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
- Latgé, J. P. (1999) Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12(2): 310–350.
- Romani, L. (2011) Immunity to fungal infections. Nat. Rev. Immunol. 11(4): 275–288.
Please follow this link
to search for certificates by lot number.